Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of propylthiouracil (PTU) and thyroxine (levothyroxine, LT4). Propylthiouracil is an antithyroid agent that inhibits thyroid hormone synthesis by blocking the organification of iodine and coupling of iodotyrosines in the thyroid gland, as well as inhibiting peripheral conversion of thyroxine (T4) to triiodothyronine (T3)[4][5]. Levothyroxine is a synthetic form of the thyroid hormone T4, used to replace or supplement endogenous thyroxine in hypothyroid states. The combination has been studied for use in specific conditions such as monocarboxylate transporter 8 (MCT8) deficiency/Allan–Herndon–Dudley syndrome, where it can help normalize serum T3 and T4 levels[1]. The combined therapy requires individualized dosing adjustments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propylthiouracil + thyroxine.